Kyowa Kirin Co., Ltd. (4151.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Kyowa Kirin Co., Ltd.
Address
Otemachi Financial City Grand Cube
Tokyo, 100-0004
Japan
Phone
81 3 5205 7200
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5669
First IPO Date
January 04, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Abdul Hafeez Mullick | President, Chief Executive Officer & Representative Director | 215M | 1967 |
| Nathan Hawes | Global Operational & Digital Transformation Head | 0 | N/A |
| Naohiko Kubo | Global Finance Head & Accounting Manager | 0 | N/A |
| Masahiro Hara | Global Procurement Head | 0 | N/A |
| Takeyoshi Yamashita | Executive VP, Chief Scientific Officer & Director | 0 | 1961 |
| Eslie Dennis | Global Medical Affairs Head | 0 | N/A |
| Stacey Minton | Global Corporate Communications Head | 0 | N/A |
| Katsuyoshi Tsukii | Executive Officer, VP & Head of Development Division | 0 | N/A |
| Shoko Itagaki | Managing Executive Officer, Chief People Officer & Global Human Resources Head | 0 | N/A |
| Yoshifumi Torii | Executive Officer, Chief Medical Officer & Global Development Head | 0 | N/A |
| Nilay Gami | Head of Global Pharmacovigilance | 0 | N/A |
| Takaaki Uochi | Head of Global Compliance & Risk Management | 0 | N/A |
| Koichi Nagano | Executive Officer and Head of Tokyo Branch - Sales & Marketing Division | 0 | N/A |
| Koji Igarashi | Chief Financial Officer | 0 | N/A |
| Kazuki Nemoto | Head of Global Legal | 0 | N/A |
| Yasuo Fujii | Chief Business Officer, VP, Managing Executive Officer & Global Business Development Head | 0 | 1964 |
Description
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
